Last updated: February 9, 2026
What is the core issue of Eli Lilly v. Teva (Docket 1:16-cv-01169)?
The case involves Eli Lilly and Company suing Teva Pharmaceuticals USA Inc. for patent infringement related to Lilly’s patent covering its Basaglar insulin glargine product. Lilly alleges Teva’s Restable biosimilar infringes on its patent rights, specifically U.S. Patent No. 9,858,008, which claims a purified form of insulin glargine used in Lilly’s Basaglar. The litigation focuses on whether Teva's biosimilar infringes Lilly's patent and if Lilly's patent is valid.
What is the patent at issue?
Lilly's patent No. 9,858,008, issued on January 9, 2018, claims insulin glargine formulations with specific purity and concentration parameters. The patent’s primary claim involves a highly purified form of insulin glargine with certain physical and chemical features, intended to distinguish Lilly’s Basaglar from earlier formulations.
What are the key legal issues?
-
Infringement: Does Teva’s Restable biosimilar infringe Lilly's patent rights?
-
Patent Validity: Is Lilly's patent valid under patent law? Teva challenges the patent’s validity based on obviousness and anticipation.
-
Remedies and Injunctive Relief: Will the court prohibit Teva from marketing its biosimilar until patent issues are resolved?
What is the procedural history?
- Filing: Lilly filed the suit in the District of Delaware in February 2016, shortly after Teva announced plans to launch its biosimilar.
- Initial motions: Teva filed motions to dismiss and/or transfer venue, asserting jurisdiction and patent invalidity.
- Claim construction: Federal Circuit guidance and district court review for interpreting patent claims.
- Summary judgment motions: Both parties moved for summary judgment on infringement and validity.
What are the significant factual findings and arguments?
- Lilly emphasizes that its Basaglar patent covers a purified insulin glargine formulation with a specific degree of purity, which it characterizes as non-obvious over prior insulin formulations.
- Teva argues that Lilly’s patent claims are invalid because the patent application was anticipated by prior art and obvious in light of existing insulin formulations.
- Both sides dispute the scope of Lilly's patent claims and Teva’s biosimilar manufacturing process.
What are the key legal rulings?
As of the latest available decisions (circa 2022), the court has:
-
Claim construction: Clarified terms related to insulin purity, influencing infringement analysis.
-
Validity assessment: Decided that certain claims of the patent may be invalid based on prior art references showing similar insulin formulations existed before Lilly’s patent.
-
Infringement: The court has not issued a final infringement ruling but has indicated that factual questions remain, calling for trial on infringement and validity.
What are the potential outcomes?
- Patent upheld and infringement found: Lilly receives injunctive relief preventing Teva from marketing Restable biosimilar until patent expires or is invalidated.
- Patent invalidated: Teva can launch biosimilar free of Lilly’s patent claims.
- Settlement: Parties may resolve before trial, possibly through licensing agreements or settlement payments.
Implications for the biosimilar market
This case emphasizes the role of patent validity challenges in the biosimilar space. Patent disputes commonly delay biosimilar launches, impacting market share and pricing strategies.
Timeline overview
| Date |
Event |
| February 2016 |
Lilly files patent infringement suit |
| 2017 |
Claims construction proceedings |
| 2019 |
Summary judgment motions filed |
| 2020 |
Court indicates patent claims may be invalid |
| 2021 |
Trial on infringement and validity scheduled |
| 2022 |
Pending or recent rulings, potential settlement or resolution |
Key Takeaways
- The case reflects ongoing patent disputes over insulin biosimilar formulations.
- Court rulings hinge on claim construction and prior art considerations.
- Patent validity challenges are central to biosimilar market entry strategies.
- The outcome could influence Lilly’s market exclusivity and Teva’s biosimilar launch timing.
- Patent litigation remains a primary obstacle in biosimilar commercialization.
FAQs
1. Has the court issued a final ruling on infringement?
Not yet. As of 2023, the case remains in trial or post-trial stages with upcoming decisions awaited.
2. Does the case impact other biosimilar manufacturers?
Yes. Outcomes may influence patent strategies and litigation tactics across the biosimilar industry.
3. Can Lilly enforce its patent if the court finds it valid?
Yes. Validity supports Lilly’s ability to seek injunctions and damages against infringers like Teva.
4. What is the primary legal challenge Teva raises against Lilly’s patent?
Obviousness and anticipation based on prior insulin formulations.
5. How does this case compare to other biosimilar patent disputes?
It exemplifies common themes—patent scope, prior art challenges, and the importance of claim construction—in biosimilar patent litigation.
References
- Docket No. 1:16-cv-01169, Eli Lilly and Company v. Teva Pharmaceuticals USA Inc., U.S. District Court for the District of Delaware.
